Evidence map›Paper›PMID 27184044›Full record

ReviewCurrent gastroenterology reports2016

Practical Approaches to "Top-Down" Therapies for Crohn's Disease.

Aranzazu Jauregui Amezaga, Gert Van Assche

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05720221 (Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05720221 completednot on this mapstarted 2021, after this paper: background citation

Adalimumab Versus Ustekinumab in Management of Inflammatory Bowel Disease in Egyptian Patients

TypeobservationalSponsorHelwan UniversityRan2021 to 2023Enrolled100ConditionsIBD
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aranzazu Jauregui AmezagaDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. aran.jauregui@gmail.com.
Gert Van AsscheDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic, progressive, and disabling disease that leads in most cases to the development of bowel damage presenting as a fistula, abscess, or stricture. For years, therapy for Crohn's disease has been based on a "step-up" approach, in which anti-TNF agents are administered after the failure of steroids and immunosuppressants. However, recent studies have suggested that early introduction of anti-TNF agents combined with immunosuppressants can modify the natural history of the disease. Patients who could benefit more of this "top-down" strategy would be those at elevated risk of a complicated or severe inflammatory bowel disease or with factors that can predict an aggressive disease course. Therefore, the management of a patient with CD should be personalized, taking into account the patient's specific characteristics and comorbidities, disease activity, site and behavior of the disease, and predictable factors of poor prognosis. A balance between medication and potential adverse effects should be achieved, trying to avoid under or overtreatment, always discussing the different therapeutic options with the patient. The natural history of ulcerative colitis differs from CD and, to date, there is not much scientific evidence on the use of early combined immunosuppression.

Indexed as

AdalimumabCrohn DiseaseDrug Administration ScheduleDrug Therapy, CombinationHealth Care CostsHumansImmunosuppressive AgentsInfliximabRisk FactorsTumor Necrosis Factor-alphaAdalimumabImmunosuppressive AgentsInfliximabTumor Necrosis Factor-alphaAdalimumabAnti-TNFCrohn’s diseaseEarly combined immunosuppressionImmunosuppressantsInfliximab

Identifiers

PMID27184044
OpenAlexW2399993563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.